ANATOMY 1 Name of the Department: Department ... - Biomeedikum

More documents

Recommendations

Info

SECTION I: APPENDIXES 12. C.Löfberg, J.Harro, C.-G.Gottfries, L.Oreland. Cholecystokinin peptides and receptor binding in Alzheimer's disease. J. Neural. Transm., 1996, v. 103, pp. 851-860. 13. T.Marandi, M.L.Dahl, R.A.Kiivet, L.Rägo, F.Sjöqvist. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Pharmacology & Toxicology, 1996, vol. 78, pp. 303-307. 14. V.Matto, J.Harro, L.Allikmets. The effects of cholecystokinin A and B receptors antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rats. Journal of Physiology and Pharmacology, 1996, vol. 47, No 4, pp. 661-669. 15. L.Nurmand. Zur Geschiehte der Pharmakologie an der Universität zu Tartu (Dorpat). Mitteilungen, 1996, No 19, 58-63. 16. T. Petteri Piepponen, Jaana Katajamäki, Toomas Kivastik, Alexander Zharkovsky, Liisa Ahtee. Behavioural and neurochemical sensitization of morphine-withdrawn rats to quinpirole. Pharmacology, Biochemistry & Behaviour, 1996, vol. 54, No 4, pp. 787-792. 17. Paavo Pokk, Toomas Kivastik, Diana Sobol, Sture Liljequist, Alexander Zharkovsky. Is upregulation of benzodiazepine receptors a compensatory reaction to reduced GABAergic tone in the brain of stressed mine? Naunyn-Schmiedeberg's Arch. Pharmacol., 1996, vol. 354, pp. 1-7. 18. Paavo Pokk, Sture Liljequist, Alexander Zharkovsky. Ro 15-4513 potentiates, instead of antagonizes, ethanol-induced sleep in mice exposed to small platform stress. European Journal of Pharmacology, 1996, pp. 19. Rein Pähkla, Jaanus Harro and Lembit Rägo. Behavioural effects of pinoline in the rat forced swimming, open field and elevated plus-maze tests. Pharmacological Research, 1996, vol. 33, No 2, pp. 1-6. 20. Rein Pähkla, Raivo Masso, Mihkel Zilmer, Lembit Rägo and Mauno M.Airaksinen. Autoradiographic localization of [ 3H]-pinoline binding sites in mouse tissues. Meth. Find. Exp. Clin. Pharmacol., 1996, vol. 18, No 6, pp. 359-366. 21. L.Rägo. Estonian Regulatory Affairs. The Regulatory Affairs Journal, 1996, vol. 7, No 7, pp. 567- 573. 22. Lembit Rägo. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. 34. Report. WHO Technical Report Series, No 863, 1996, pp. 115-154. 23. J.M.Aiache, A.Andayaningsih, N.Aoyagi, E.Beyssac, D.Blois, H.Blume, A.Bondani, M.Cone, M.N.Dauramanzi, T.Fushimi, U.Gundert-Remy, C.G. Guyer, F.D.Juma, G.Kreutz, L.Lacy, I.J.McGilveray, O.Morin, R.Nedich, R.Nijkerk, H.P.Osterwald, T.L.Paal, R.N.Patnaik, J.M.Peon, M.C.Pikaert, L.Rägo, B.Rosenkranz, H.Scheinin, N.Uemura, R.L.Williams. Multisource (generic) pharmaceutical products: quidelines on registration requirements to establisch interchangeability. In the book: Quality Assurance of Pharmaceuticals. A compendium of quidelines and related materials, 1997, vol.1, World Health Organization, Geneva, pp. 62-104. 24. J.Harro, C.Löfberg, R.Pähkla, V.Matto, L.Rägo, L.Oreland, L.Allikmets. Different molecular forms of cholecystokinin and CCKb receptor binding in the rat brain after chronic antidepressant treatment. Naunyn-Schmiedeberg’s Arch. Pharmacol., 1997, vol355, pp. 57-63. 25. A.Kalda, E.Eriste, V.Vassiljev,A.Zharkovsky. Medium transitory oxygen-glucose deprivation induced both apoptosis and necrosis in cerebella granule cells. Neuroscience Letters, 1997, vol.239, pp. 1-4. 26. A.Kask, J. Harro, P.Tuomainen, L.Rägo, P.Männisto. Overflow of noradrenalive and dopamine in frontal cortex after [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. Naun-Schmiedeberg’s Arch. Of Pharmacology, 1997, vol. 355, No 2, p.267-272. 27. A.Kask, L.Rägo,J.Harro. α-Helical CRF9-41 prevents anxioogenic-like effect of NPY Y1 receptor antagonist BIBP3226 in rats. NeuroReport, 1997, vol. 8, No 16, p. 3645-3647. 28. T.Marandi,M.-L.Dahl, L.Rägo, R.Kiivet, F.SjöQvist. Debrioquine and S-mephenytoin hydroxylation polymorphisms in Russian population living in Estonia. Eur. J. of Clin. Pharmacol., 1997, vol. 53, Issue ¾, pp.257-260. 29. V.Matto, L.Allikmets, T.Skrebuhhova. Apomorphine-induced aggressiveness and [3H]citalopram binding after antidepressant treatment in rats. Pharmacol. Biochem. Behav., 1997, vol. 59, No 2, pp.1-6. 30. V. Matto,J.Harro, L.Allikmets. The effect of drugs acting on CCK receptors and rat free expioration in the exploration box. J. of Physiol. Pharmacol., 1997, vol. 48, No 2, pp. 239-251. 31. V.Matto, J.Harro, L.Allikmets. The effect of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. Neuropharmacology, 1007, vol.36, No 3, pp.389-396. 54
PHARMACOLOGY 32. M.Otter, K.Otter. Qutstanding representative of Estonian experimental pharmacology: Georg Kingisepp. Acta Medico-Historica Rigensia, 1997, vol. III(XXII), p. 217-221. 33. M.Otter, T.Skrebuhhova, V.Matto, J.Harro. Measurement of exploratory behaviour in rat. Proaeding of the Sixt FELASA Symposium, 19-21 June 1997, Basel Swtzerland.In: Harmonization of Laboratory Animal Husbandry, 1997, pp. 21-23. 34. M.-H.Otter, V.Matto, R.Sôukand, T.Skrebuhhova, L.Allikmets, J.Harro. Characterization of rat exploratory behaviour using the exploratory box test. Meth. Find. Clin. Pharmacol., 1997, vol. 19, No 10, pp. 683-691. 35. T.P.Piepponen, T.Kivastik, J.Kivastik, J.Katajamäki, A.Zharkovsky. L.Ahtee. Involvement of opioid μ1 receptors in morphine-induced conditioned place preference in rats. Pharmacol. Biochem. Behav., 1997, vol. 58, No 1, pp. 275-279. 36. P.Pokk, A.Zharkovsky. The effect of flumazenil, Ro 15-4513 and β-CCM on the behaviour of control and stressed mice in the plus-maze test. J. of Physiol. Pharmacol., 1997, vol. 48, No 2, pp. 253-261. 37. R.Pähkla, R.Masso, L.Rägo, M.M.Airaksinen. [3H]pinoline binding sites: autoradiographic visualization and characterization. Acta Medica Baltica, 1996, vol. 3, No 3, pp. 218-226. 38. R.Pähkla, L.Rägo. High affinity binding of [3H]citalopram in rat adrenals. Pharm. Pharmacol. Lett., 1997, vol. 7, No 1, pp. 13-16. 39. R.Pähkla, L.Rägo, J.Callaway, M.M.Airaksinen. Binding of pinoline on the 5-hydroxytryptamine transporter: competitive interaction with [3H]citalopram. Pharmacol. Toxicol., 1997, vol. 80, pp. 122-126. 40. L.Rägo. Pharmaceutical inspection in Estonia. The Regulatory Affairs Journal, 1997, vol. 8, No 4, pp. 248-251. 41. J.Shlik, V.Vasar, A.Aluoja, P.H.Kingisepp, K.Jagomägi, V.Vasar, L.Rägo, J.Bradwejn. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biology Psychiatry, 1997, vol. 42, No 3, pp. 206-212. 42. L.H.Allikmets, L.G.Polevoi, A.M.Zharkovsky, V.I.Gunar, V.M.Kopelevitsh, L.N.Bulanova, M.J.Otter. Neurobutaal (kaltsiumoksübutüraat) - uus nootroopne preparaat. I. Farmakoloogiline skriining ja biokeemilised uuringud. Nootroopsed preparaadid. Moskva, 1998, lk. 138-148 (vene keeles). 43. A.Kalda, E.Eriste, V.Vassiljev, A.Zharkovsky. Medium transitory oxygen- glucose deprivation induced both apoptosis and necrosis in cerebellar granule cells. Neuroscience Letters, 1998, vol. 240, pp. 21-24. 44. A.Kask, J.Harro, L.Rägo. Opposite effects of [Leu 13 , Pro 34 ]NPY and NPY13-36 on hypnotic response to α2-adrenoceptor agonist dexmedetomidine microinjected into rat locus coeruleus. Neuroscience Research Communications, 1998, vol. 23, No 1, pp. 41-43. 45. A.Kask, F.Mutulis, R.Muceniece, R.Pähkla, I.Mutule, J.E.S.Wikberg, L.Rägo, H.B.Schiöth. Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. Endocrinology, 1998, vol. 139, No 12, pp. 5006-5014. 46. A.Kask, L.Rägo, J.Harro. Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus. Brain Research, 1998, vol. 788, pp. 345-348. 47. A.Kask, L.Rägo, J.Harro. NPY Y1 receptors in the dorsal periaqueductal gray matter regulate anxiety in the social interaction test. NeuroReport, 1998, vol. 9, pp. 2713-2716. 48. A.Kask, L.Rägo, J.Harro. Anxiolytic-like effect of neuropeptide NPY Y1 receptor antagonist BIB3226 administered into the dorsal periaqueductal gray matter in rats. Regulatory Peptides, 1998, vol. 75-76, pp. 255-262. 49. A.Kask, L.Rägo, J.Harro. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. British Journal of Pharmacology, 1998, vol. 124, pp. 1507-1515. 50. A.Kask, L.Rägo, F.Mutulis, R.Pähkla. Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats. Biochemical and biophysical Research Communications, 1998, vol. 245, pp. 90-93. 51. A.Kask, L.Rägo, P.Korrovits, J.E.S.Wikberg, H.B.Schiöth. Evidence that orexigenic effects of melanocortin 4 receptor antagonist HS014 are mediated by neuropeptide Y. Biochemical and Biophysical Research communications, 1998, vol. 248, pp. 245-249. 52. A.Kask, L.Rägo, J.E.S.Wikberg, H.B.Schiöth. Evidence for involvement of the melanocortin MC4 receptor in the effect of leptin on food intake and body weight. European J. Pharmacology, 1998, vol. 360, pp. 15-19. 53. J.Katajamäki, A.Honkanen, T.P.Piepponen, I.-B.Linden, A.Zharkovsky, L.Ahtee. Conditioned placepreference induced by a combination of L-Dopa and a COMT inhibitor, entacapone, in rats. Pharmacol. Biochem. Behav., 1998, vol. 60, No 1, pp. 23-26. 55
Page 1 and 2:
ANATOMY Name of the Department: Dep
Page 3 and 4: ANATOMY Weaknesses • Limited time
Page 5 and 6: ANATOMY To continue the integration
Page 7 and 8: ANATOMY been reduced from 6 CP to 5
Page 9 and 10: IV. TEACHING RESOURCES ANATOMY 9. I
Page 11 and 12: APPENDIX I-I Visits of the Departme
Page 13 and 14: APPENDIX I-VI Publications of the D
Page 15 and 16: PAPERS IN ESTONIAN JOURNALS ANATOMY
Page 17: APPENDIX I-VII Academic and adminis
Page 20 and 21: SECTION I: APPENDIXES societies: Mo
Page 23 and 24: BIOCHEMISTRY Name of Department: De
Page 25 and 26: BIOCHEMISTRY eliminated. Such alter
Page 27 and 28: BIOCHEMISTRY Biochemistry: resource
Page 29 and 30: APPENDIX I-II BIOCHEMISTRY Postgrad
Page 33 and 34: BIOCHEMISTRY 4. Dementia and Geriat
Page 35 and 36: BIOCHEMISTRY 51. J Cardiovascular r
Page 40 and 41: SECTION I: APPENDIXES ship in acade
Page 42 and 43: SECTION I: SELF-EVALUATION 42 proac
Page 44 and 45: SECTION I: SELF-EVALUATION 44 the a
Page 46 and 47: SECTION I: SELF-EVALUATION 46 The f
Page 48 and 49: SECTION I: SELF-EVALUATION 48 macol
Page 50 and 51: SECTION I: APPENDIXES APPENDIX I-I
Page 52 and 53: SECTION I: APPENDIXES APPENDIX I-IV
Page 56 and 57: SECTION I: APPENDIXES 54. C.Löfber
Page 58 and 59: SECTION I: APPENDIXES 100. Kalda A.
Page 60 and 61: SECTION I: APPENDIXES 12. M. Otter.
Page 66 and 67: SECTION I: APPENDIXES Community 5th
Page 68 and 69: SECTION I: APPENDIXES Tartu as a ph
Page 71 and 72: PHYSIOLOGY Name of Department: Depa
Page 73 and 74: PHYSIOLOGY 3. Describe the strength
Page 75 and 76: PHYSIOLOGY students. According to t
Page 77 and 78: PHYSIOLOGY Physiology: resource eva
Page 79 and 80: PHYSIOLOGY 1999 Kersti Jagomägi, s
Page 83: PHYSIOLOGY 67. J.Kivastik, P.-H.Kin
Page 87 and 88: APPENDIX I-VIII Curriculum Vitae of
Page 89 and 90: PHYSIOLOGY meeting on physiology" 1
Page 91: PHYSIOLOGY University of Kuopio;vis
Page 94 and 95: SECTION I: SELF-EVALUATION ceptual
Page 96 and 97: SECTION I: SELF-EVALUATION 96 stude
Page 98 and 99: SECTION I: SELF-EVALUATION VI. FUTU
Page 100 and 101: SECTION I: APPENDIXES APPENDIX I-I
Page 102 and 103: SECTION I: APPENDIXES APPENDIX I-VI
Page 104 and 105:
SECTION I: APPENDIXES 2. Mikelsaar
Page 107:
APPENDIX I-VII Academic and adminis
Page 110 and 111:
SECTION I: APPENDIXES was supported
Page 113 and 114:
PATHOLOGICAL ANATOMY AND FORENSIC M
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
APPENDIX I-I PATHOLOGICAL ANATOMY A
Page 125 and 126:
Page 127:
Page 130 and 131:
SECTION I: APPENDIXES DRIKKIT, ILON
Page 132 and 133:
SECTION I: SELF-EVALUATION 2. How h
Page 134 and 135:
SECTION I: SELF-EVALUATION 8. Is th
Page 136 and 137:
SECTION I: APPENDIXES APPENDIX I-I
Page 138 and 139:
SECTION I: APPENDIXES 1999 Argo Soo
Page 140 and 141:
SECTION I: APPENDIXES APPENDIX I-V
Page 142 and 143:
SECTION I: APPENDIXES 8. Harro J, S
Page 144 and 145:
SECTION I: APPENDIXES 98. Põlluste
Page 147:
Page 150 and 151:
SECTION I: APPENDIXES Nutritional S
Page 152 and 153:
SECTION I: APPENDIXES Economists Cu
Page 154 and 155:
SECTION I: SELF-EVALUATION • Biol
Page 156 and 157:
SECTION I: SELF-EVALUATION 156 The
Page 158 and 159:
SECTION I: SELF-EVALUATION 158 2. C
Page 160 and 161:
SECTION I: SELF-EVALUATION 160 2. T
Page 162 and 163:
SECTION I: SELF-EVALUATION II. EVAL
Page 164 and 165:
SECTION I: SELF-EVALUATION 164 Subj
Page 166 and 167:
Page 168 and 169:
SECTION I: APPENDIXES APPENDIX I-V
Page 170 and 171:
SECTION I: APPENDIXES 31. Waldmann
Page 173:
Page 176 and 177:
SECTION I: APPENDIXES partment of G
Page 178 and 179:
SECTION I: APPENDIXES arum (MSc) in
Page 180 and 181:
SECTION I: SELF-EVALUATION 180 1. T
Page 182 and 183:
SECTION I: SELF-EVALUATION 182 Duri
Page 184 and 185:
SECTION I: SELF-EVALUATION 184 2. B
Page 186 and 187:
Page 188 and 189:
SECTION I: APPENDIXES 19. Tiivel T.
Page 191 and 192:
APPENDIX I-VIII Curriculum Vitae of
Page 193 and 194:
IMMUNOLOGY Name of the Department:
Page 195 and 196:
IMMUNOLOGY equipped with English la
Page 197 and 198:
IMMUNOLOGY Immunology: resource eva
Page 199 and 200:
APPENDIX I-II IMMUNOLOGY Postgradua
Page 201 and 202:
IMMUNOLOGY 19. Juhela S, Hyöty H,
Page 203:
Page 206 and 207:
SECTION I: APPENDIXES Laboratory of
show all

ANATOMY 1 Name of the Department: Department ... - Biomeedikum

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?